Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) reported a 53% year-over-year reduction in operating expenses to $2.29 million and a 47% decrease in general and administrative expenses to $1.76 million for the second quarter of 2026. The company's cash, cash equivalents, and digital assets totaled approximately $9.5 million as of June 30, up from $4.1 million at the end of 2025. Management stated that current liquidity is sufficient to fund planned operations until at least October 2027, assuming the first-half 2026 cash burn rate.
Following the quarter, the U.S. Food and Drug Administration approved Quantum's Investigational New Drug application for Lucid-MS, allowing the company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. This advancement is significant because it moves the drug candidate closer to a potential treatment for a condition with unmet medical need.
The company's focus on neurodegenerative and metabolic disorders, including alcohol misuse disorders, is underscored by its pipeline. Quantum retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets an over-the-counter version of its UNBUZZD product. The agreement includes royalty payments of 7% of sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of rights to develop pharmaceutical and medical formulations of similar products.
These financial results and regulatory milestone come at a time when biotech companies are under pressure to manage cash while advancing clinical programs. The reduced expenses and extended cash runway provide Quantum with a stronger position to support the upcoming Phase 2 trial. The approval of the IND application is a crucial step for Lucid-MS, which could address a significant patient population if successful.
For more details on the full press release, visit https://nnw.fm/dlAAe. Information about the company is available in its newsroom at https://ibn.fm/QNTM.
The company's forward-looking statements involve risks and uncertainties, as detailed in its SEC filings. Investors are advised to consider these factors when evaluating the company's prospects.
